FDA Clears Opicapone (Ongentys) as Add-On Therapy in PD FDA Clears Opicapone (Ongentys) as Add-On Therapy in PD

Opicapone is an oral COMT inhibitor approved as add-on therapy for patients with Parkinson disease who experience ' off ' periods while receiving a stable levodopa/carbidopa regimen.FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news